Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea Steps Up AI Adoption In Drug Discovery, Repositioning And Surveillance

Executive Summary

South Korea is stepping up the adoption of artificial intelligence to speed up drug development by selecting discovery, repositioning and smart drug surveillance as three initial focus areas for new AI/big data platforms.

You may also be interested in...



Digital Health Trends: Asia Catching Up But Hurdles Remain

Digital health initiatives are rapidly emerging in Asia amid robust innovation and rising R&D activities in the region, but there are still some hurdles to overcome. An executive from Pfizer talks to Scrip about some of the major trends, opportunities and challenges.

How Can Korea Grab Window Of Opportunity In AI Drug Development?

Participants at a recent policy forum in Seoul stressed the need to secure appropriate technology and expertise, unify government support and draw up a joint cooperation plan between industry and government as key factors in advancing AI-guided new drug development in South Korea.

Korean Firms Pursue “Select And Focus” Strategy To Accelerate R&D

South Korean pharma and biotech companies are opting to spin off certain businesses and set up new subsidiaries to speed up R&D progress and tap funding opportunities. The move, which has become more visible in the past few years is in line with global biopharma trends, although the reasons may vary.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel